IP Generator, Inc., (“IPG”) and La Jolla Institute for Immunology (“LJI”), based in La Jolla, California, USA, have entered into a Master Collaborative Research and Development Agreement (“this agreement”) dated May 12, 2022. This agreement establishes a formal framework for the incorporation of promising drug target leads from LJI into IPG’s drug discovery platform. The program enables LJI to propose drug targets to IPG for identification and development of lead compounds or modalities with the goal of licensing clinical development candidates to pharmaceutical companies. IPG aims for the efficient creation of innovative medicines and hopes to contribute to solving global social issues by reducing healthcare costs and expanding access to …
Over 20 companies have accepted to join IPG membership
IP Generator, Inc., (“IPG”) operates IPG membership, which was established with the mission of providing pharmaceutical companies with more efficient access to clinical development drug candidates. We are happy to announce today that the number of member companies accepting IPG membership has exceeded 20 domestic and foreign pharmaceutical companies. Eight of the twenty-one member companies are global pharmaceutical companies from abroad, and seven of the fifteen top pharmaceutical companies by revenue in the world (according to our research) have accepted to join the IPG membership. IPG is a platform provider for drug discovery and development in pre-clinical stage, and the company efficiently generates high-quality clinical development candidates from drug discovery …
Continue reading “Over 20 companies have accepted to join IPG membership”
IP Generator, Axcelead, and Axcelead Drug Discovery Partners Signed a Comprehensive Business Alliance Agreement
To Establish a Platform for the Efficient and High-quality Drug Discovery Aiming to Resolve Social Issues by Reducing Medical Costs